Figure 1 Mean C-reactive Protein Levels At The End Of Parts 1, 2 And 3 Of Study 1. (Ilaris 01)
Ilaris Injection, Solution
Product Images NDC 0078-0734
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Ilaris (NDC 0078-0734). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Principal Display Panel – Package Label – 150 mg/vial (Ilaris 02)
ILARIS Ry is a subcutaneous injection medication with a concentration of 150 mg/mL produced by Novartis. It comes in a single-dose vial, and any unused medication should be discarded. The medication guide enclosed with the package should be thoroughly reviewed before administration. Storage of the medication should be within the temperature range of 2-8 degrees Celsius.*
Figure 2. Kaplan-meier Estimates Of The Probability To Stay Flare-free In Part Ii Of Sjia Study 2 By Treatment (Ilaris 03)
This seems to be a graph displaying the Kaplan-Meier estimate for the treatment group (ACZ885) and a control group (Placebo) in weeks using percentages. It appears to show the number of patients at risk and the number of weeks in Part II of the study. The ACZ885 group seems to have more patients at risk than the placebo group at each week. The text is only giving numerical data and no context is provided.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
